So what exactly is treatment resistant depression? Well, most clinicians agree that this term describes people who are currently struggling with depression and has tried counseling and at least two different medications with little to no improvement. More than 16 million adults in the U.S. are affected by depression and up to one third of those don't respond to typical treatment. Those suffering from treatment resistant depression often feel hopeless.
The good news is in March 2019 the FDA approved a new option, Spravato (esketamine) nasal spray. "There has been a long-standing need for additional effective treatments for treatment-resistant depression, a serious and life-threatening condition," said Tiffany Farchione, M.D., acting director of the Division of Psychiatry Products in the FDA's Center for Drug Evaluation and Research.
Integrative Wellness Solutions is excited to begin offering Spravato as a treatment option for patients starting October 2019.